{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Progression of Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Response not available"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"To determine the objective radiologic response rate of pemetrexed and gemcitabine in patients with recurrent or metastatic Head and Neck Squamouse Cell Carcinoma.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.","id":"OG000","title":"Pemetrexed Plus Gemcitabine"}],"paramType":"NUMBER","populationDescription":"All assessable patients as indicated in the protocol.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Objective Response","type":"PRIMARY","unitOfMeasure":"participants"}